Clincosm LogoSign in Get a demo

Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma

Sponsor
Genzyme, a Sanofi Company (Industry)
Overall Status
Completed
CT.gov ID
NCT00068211
Collaborator
(none)
19
Locations
29
Duration (Months)

Study Details

Study Description

Brief Summary

This is a Phase II, non-randomized, open label study of ILX651 in patients with inoperable locally advanced or metastatic melanoma. Approximately 60 patients will be enrolled in this study that is expected to last 18 months. All patients will be treated with ILX651 administered IV daily for 5 consecutive days once every 21 days. The primary objective of this study is to determine the overall response rate for all patients who are treated with ILX651. The secondary objectives are to determine the progression free survival at 18 weeks, duration of response, time to tumor progression, survival, safety/tolerability of ILX651 and to evaluate the pharmacokinetic profile.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Inoperable Locally Advanced or Metastatic Melanoma.
Study Start Date :
Aug 1, 2003
Actual Study Completion Date :
Jan 1, 2006

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Histologically or cytologically confirmed inoperable locally advanced or metastatic malignant melanoma.

    • Measurable disease. Measurable lesions should be outside the field of radiation. Where measurable lesions are within a previously irradiated field, there must be objective evidence of progression of the lesion prior to patient enrollment.

    • Male or female patients greater than or equal to 18 years of age.

    • ECOG performance status of 0 or 1.

    • Must have adequate organ and immune system function as indicated by the following laboratory values, obtained less than or equal to 2 weeks prior to registration: A. Absolute neutrophil count(ANC) greater than or equal to 1.5 x 1,000,000,000. B.Hemoglobin greater than or equal to 9.0 g/Dl. C. Platelet count greater than or equal to 100 x 1,000,000,000/L. E. Serum creatinine or calculated creatinine clearance less than or equal to 1.5 mg/dL or greater than or equal to 60 mL/min. F. Serum total bilirubin less than or equal to 2.0 mg/dL. G. AST and ALT less than or equal to 3 times the upper limit of normal (ULN) OR less than 5 times the ULN if secondary to liver metastases. H. Alkaline phosphatase less than or equal to 5 times the ULN (unless bone metastases are present in the absence of liver metastases).

    • Anti-cancer therapy, major surgery, or irradiation must have been completed at least 4 weeks before enrollment in this study. Patient must have recovered from the acute side effects incurred as a result of previous therapy.

    • Female patients with childbearing potential must have a negative pregnancy test within 7 days of study enrollment. Men and women of reproductive potential must use an effective contraceptive method while enrolled in the study.

    • Signed informed consent (includes HIPAA authorization).

    Exclusion Criteria:

    • Patients with uncontrolled congestive heart failure or angina, patients with a history of myocardial infarction within 2 months of enrollment, or patients with cardiac functional capacity Class III or IV as defined by the New York Heart Association Classification.

    • Previously treated with systemic chemotherapy.

    • Prior radiotherapy to the only site of measurable disease.

    • Known hypersensitivity to study drug or its analogs.

    • Active ocular melanoma. Patients with a primary diagnosis of ocular melanoma will not be excluded provided the primary ocular melanoma is no longer present and the recurrence is distal.

    • Use of investigational agents within previous 30 days.

    • Known, active infection, or known HIV positive or presence of an AIDS related illness.

    • Active secondary malignancy.

    • Presence of symptomatic active brain metastases, including leptomeningeal involvement. Prior evidence of brain metastasis is permitted only if the patient has been in clinical complete remission for at least 1 month after therapy.

    • Uncontrolled hypertension. Patients with hypertension must have their blood pressure controlled on antihypertensive medications as assessed by the investigator.

    • Patients with prior radiation therapy to greater than 25% of the bone marrow (eg, no whole pelvic irradiation is allowed).

    • Any significant concurrent disease or illness, or psychiatric disorders or alcohol or chemical abuse that would, in the opinion of the investigator, compromise patient safety or compliance, or interfere with the interpretation of study results.

    • Pregnant or lactating females.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Arizona Cancer Center at Scottsdale Scottsdale Arizona United States 85285
    2 Univ of Arizona Cancer Center Tucson Arizona United States 85724
    3 USC / Norris Cancer Center Los Angeles California United States 90033
    4 Cancer Institute Medical Group Santa Monica California United States 90404
    5 Univ of Colorado Cancer Center/ Anschutz Cancer Aurora Colorado United States 80010
    6 US Oncology / Cancer Centers of Florida Orlando Florida United States 32806
    7 US Oncology / Kansas City Oncology Overland Park Kansas United States 66210
    8 Beth Israel Medical Center Boston Massachusetts United States 02215
    9 US Oncology / Kansas City Oncology and Hematology Kansas City Missouri United States 64111
    10 Center for Cancer Care Research St. Louis Missouri United States 63141
    11 US Oncology / Albany Regional Cancer Center Albany New York United States 12208
    12 US Oncology / Dayton Oncology and Hematology Kettering Ohio United States 45409
    13 US Oncology / Cancer Centers of the Carolinas Greenville South Carolina United States 29615
    14 US Oncology / Mary Crowley Medical Research Dallas Texas United States 75246
    15 US Oncology /Texas Oncology Ft. Worth Texas United States 76104
    16 St. Luke's Episcopal Hospital Houston Texas United States 77030
    17 US Oncology/ Tyler Cancer Center Tyler Texas United States 75702
    18 Seattle Cancer Care Alliance Seattle Washington United States 98109
    19 US Oncology / Cancer Care Northwest Spokane Washington United States 99218

    Sponsors and Collaborators

    • Genzyme, a Sanofi Company

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00068211
    Other Study ID Numbers:
    • ILX651-211
    First Posted:
    Sep 11, 2003
    Last Update Posted:
    Mar 5, 2015
    Last Verified:
    Mar 1, 2015
    Keywords provided by , ,
    Metastatic Melanoma
    Melanoma
    Inoperable Locally Advanced Melanoma
    Additional relevant MeSH terms:
    Melanoma

    Study Results

    No Results Posted as of Mar 5, 2015